Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fasting Condition
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
Summary
- Conditions
- Fasting State
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Crossover AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 45 years
- Gender
- Both males and females
Description
Primary Objective of this pivotal study was to assess the bioequivalence between Test Product: Levocetirizine Dihydrochloride 5 mg Tablets of M/s Ipca Laboratories Limited, India and the corresponding Reference Product: Xyzal® (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA, under ...
Primary Objective of this pivotal study was to assess the bioequivalence between Test Product: Levocetirizine Dihydrochloride 5 mg Tablets of M/s Ipca Laboratories Limited, India and the corresponding Reference Product: Xyzal® (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA, under fasting condition in normal, healthy, adult, human subjects in a randomized crossover study. Secondary Objective was to monitor the safety and tolerability of a single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets in normal,healthy, adult, human subjects. The study was conducted with 28 healthy adult subjects. In each study period, a single 5 mg dose of either test or reference was administered to the subjects as per the randomization schedule in each study period with about 240 mL of water at ambient temperature in sitting position. The duration of the clinical phase was approximately 11 days including washout period of at least 7 days between administrations of study drug in each study period.
Tracking Information
- NCT #
- NCT01557439
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Dr. Rupesh Vala, M.B.B.S. Accutest Research Lab (I) Pvt. Ltd.